Sweden Country Commercial Guide
Learn about the market conditions, opportunities, regulations, and business conditions in sweden, prepared by at U.S. Embassies worldwide by Commerce Department, State Department and other U.S. agencies’ professionals
Select Country Guide
eHealth
Last published date:

Healthcare
The Swedish healthcare system is decentralized, with responsibilities shared across three administrative levels: the central government, the regions, and the municipalities. The 21 regional councils (regions) are responsible for financing and delivering health services, while the 290 municipalities handle elderly care and social services. In 2023, healthcare expenditures in Sweden amounted to 11.2% of GDP ($73.8 billion). Private healthcare plays a supplementary role. Some healthcare services, especially in primary care and elderly care, are outsourced to private providers.
In 2024, Newsweek included several Swedish hospitals in its Top 250 Global Hospitals list: Karolinska University Hospital (no. 7), Sahlgrenska University Hospital (no. 74), Akademiska Hospital (no. 75), Skåne University Hospital (no. 133), Linköping University Hospital (no. 205), and Norrlands University Hospital (no. 230).
U.S. firms entering the Swedish market should expect a high level of competition. Establishing a local presence, via agents/distributors or wholly owned subsidiaries, is often strongly recommended.
 

Medical Equipment & Devices
Opportunities for companies can be found in the field of high-quality, technically advanced devices that improve efficiency, reduce hospital stays, and enable remote or outpatient care. Digital health tools (electronic health records, telehealth, clinical decision support), imaging, monitoring systems, minimally invasive surgical tools, wearables, and artificial intelligence solutions are also among promising segments. Collaboration with Swedish health innovation test beds, regional innovation arms, and public procurement pilots is recommended.
Other potential areas of growth can be found in AI image recognition, providing more accurate diagnoses, to lower costs. Drone technologies that could improve healthcare logistics is also an area where there is potential. 
Regulation of medical devices and diagnostics in Sweden follows the EU Medical Devices Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR). Clinical investigations, conformity assessments, and post-market surveillance are required as per EU rules. 
Medtech and related products benefit from free movement of goods within the EU, harmonized regulatory frameworks, and relatively high domestic innovation capacity.
 

Pharmaceuticals & Biotech
Sweden’s life science sector includes hundreds of public research centers, university labs, and clinical research infrastructures, with major concentrations in Stockholm–Uppsala, Gothenburg, and Southern Sweden (Skåne). The country also fosters innovative start-ups through incubators and science parks such as Medicon Village in Lund and the Karolinska Institute and hospital in Stockholm.
Domestic pharmaceutical production remains significant for specialized and high value products. The Swedish system of drug reimbursement and pricing is tightly regulated. Marketing of medicines, monitoring of adverse reactions, and reimbursement decisions are overseen through regulatory agencies (e.g. the Swedish Medical Products Agency, Läkemedelsverket).
Pharmaceuticals in hospitals, outpatient settings, and general retail are distributed via licensed wholesalers and pharmacies. Reimbursement systems and reference pricing influence market access for new and generic drugs.
Biotech and diagnostics are important growth areas in Sweden’s life science landscape. Swedish biotech firms work on gene therapies, antibody technologies, precision medicine, oncology, infectious and inflammatory diseases, neurological disorders, cardiovascular diseases, and rare (orphan) diseases. 
Sweden’s biotech advancements provide promising opportunities for U.S. biotech firms looking to develop products and advance new treatments. Sweden’s open, export-oriented market and EU membership facilitate access to the broader European market. Innovative therapies, biologics, orphan drugs, precision medicines, advanced therapeutics (e.g. gene / cell therapies) have potential, especially if in line with Swedish/regional priorities (rare diseases, personalized medicine, aging population).
Sweden also has a strong tradition of health registries and biobanks. National health and disease registers (for example, cancer registers, quality registers for specific clinical conditions) have long been used for surveillance, quality monitoring, and research
Sweden applies EU regulation (e.g. IVDR) for diagnostics and biological / combination products. The regulatory framework is evolving with the EU oversight.
 

Resources

  • SwedenBIO – industry association for Swedish life sciences industry in Sweden, with more than 250 members, covering the whole ecosystem of the life-science sector. SwedenBio members are engaged in R&D, production, and sales in fields such as biotech, medtech, diagnostics, and pharma. 

  • Vinnova – Sweden’s innovation agency, supports health / life science projects

  • Swedish Medical Products Agency (Läkemedelsverket) – regulates drugs, biologics, medical devices

  • Swedish regions / county councils – purchasers and operators of health services

  • Karolinska Institute, Uppsala (Stuns), Lund University (and Medicon Village), Gothenburg – leading academic / clinical partners / research hubs

  • Regional health innovation testbeds / platforms – e.g. digital health pilots, regional clinical trials networks

  • Medicon Village/Valley in Southern Sweden, a life science cluster with strong medtech/biotech activity and collaboration networks.

  • Swedish Life Science Database– data resource on Swedish life science companies

Trade Events

European Human Genetics Conference (EHGC) 2026

  • Dates/Location: 1–4 June 2026, Swedish Exhibition & Congress Centre, Gothenburg

  •  Overview: The flagship European conference on human genetics and genomics, featuring plenaries, industry symposia, and exhibit halls around diagnostics, sequencing, and personalized medicine.

     

Vitalis 2026

  • Dates/Location: 4–7 May 2026, Svenska Mässan (Swedish Exhibition Centre), Gothenburg 

  • Overview: The largest eHealth and welfare-technology conference in Scandinavia. Brings together healthcare providers, municipalities, digital health firms, researchers, and policy actors to showcase innovation, network, and share best practices.

     

Nordic Life Science Days (NLS Days) 2026

  • Dates/Location: 15–17 September 2026, Stockholm

  • Overview: The premier life-science partnering event in the Nordics, emphasizing biotech, pharma, digital health, diagnostics, and investment matchmaking.

 

Local Commercial Specialist: Johan Bjorkman, Johan.Bjorkman@trade.gov

×

Global Business Navigator Chatbot Beta

Welcome to the Global Business Navigator, an artificial intelligence (AI) Chatbot from the International Trade Administration (ITA). This tool, currently in beta version testing, is designed to provide general information on the exporting process and the resources available to assist new and experienced U.S. exporters. The Chatbot, developed using Microsoft’s Azure AI services, is trained on ITA’s export-related content and aims to quickly get users the information they need. The Chatbot is intended to make the benefits of exporting more accessible by understanding non-expert language, idiomatic expressions, and foreign languages.

Limitations

As a beta product, the Chatbot is currently being tested and its responses may occasionally produce inaccurate or incomplete information. The Chatbot is trained to decline out of scope or inappropriate requests. The Chatbot’s knowledge is limited to the public information on the Export Solutions web pages of Trade.gov, which covers a wide range of topics on exporting. While it cannot provide responses specific to a company’s product or a specific foreign market, its reference pages will guide you to other relevant government resources and market research. Always double-check the Chatbot’s responses using the provided references or by visiting the Export Solutions web pages on Trade.gov. Do not use its responses as legal or professional advice. Inaccurate advice from the Chatbot would not be a defense to violating any export rules or regulations.

Privacy

The Chatbot does not collect information about users and does not use the contents of users’ chat history to learn new information. All feedback is anonymous. Please do not enter personally identifiable information (PII), sensitive, or proprietary information into the Chatbot. Your conversations will not be connected to other interactions or accounts with ITA. Conversations with the Chatbot may be reviewed to help ITA improve the tool and address harmful, illegal, or otherwise inappropriate questions.

Translation

The Chatbot supports a wide range of languages. Because the Chatbot is trained in English and responses are translated, you should verify the translation. For example, the Chatbot may have difficulty with acronyms, abbreviations, and nuances in a language other than English.

Privacy Program | Information Quality Guidelines | Accessibility